WO2022263935A1 - Pharmacutical composition comprising remogliflozin etabonate, metformin hydrochloride and vildagliptin - Google Patents
Pharmacutical composition comprising remogliflozin etabonate, metformin hydrochloride and vildagliptin Download PDFInfo
- Publication number
- WO2022263935A1 WO2022263935A1 PCT/IB2022/051919 IB2022051919W WO2022263935A1 WO 2022263935 A1 WO2022263935 A1 WO 2022263935A1 IB 2022051919 W IB2022051919 W IB 2022051919W WO 2022263935 A1 WO2022263935 A1 WO 2022263935A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vildagliptin
- remogliflozin etabonate
- metformin hydrochloride
- amount
- starch
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 115
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 title claims abstract description 105
- 229960001254 vildagliptin Drugs 0.000 title claims abstract description 104
- 229950011516 remogliflozin etabonate Drugs 0.000 title claims abstract description 95
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 title claims abstract description 95
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 229960004329 metformin hydrochloride Drugs 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims description 87
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 229960003105 metformin Drugs 0.000 claims description 39
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 239000011230 binding agent Substances 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 238000004090 dissolution Methods 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 229940032147 starch Drugs 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229960004977 anhydrous lactose Drugs 0.000 claims description 6
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
- 239000008109 sodium starch glycolate Substances 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 229940033134 talc Drugs 0.000 claims description 6
- 235000012222 talc Nutrition 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229940014259 gelatin Drugs 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 229940057948 magnesium stearate Drugs 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 229920001592 potato starch Polymers 0.000 claims description 3
- 229940116317 potato starch Drugs 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000015424 sodium Nutrition 0.000 claims description 3
- 229940083542 sodium Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 2
- 238000009490 roller compaction Methods 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 239000012738 dissolution medium Substances 0.000 claims 4
- 239000008363 phosphate buffer Substances 0.000 claims 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- 150000003839 salts Chemical class 0.000 abstract description 51
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 abstract description 22
- 229940126844 remogliflozin Drugs 0.000 abstract description 22
- 150000002148 esters Chemical class 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 15
- 239000003472 antidiabetic agent Substances 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000007787 solid Substances 0.000 description 48
- 239000008203 oral pharmaceutical composition Substances 0.000 description 47
- 239000003826 tablet Substances 0.000 description 43
- 239000008187 granular material Substances 0.000 description 38
- 239000003814 drug Substances 0.000 description 21
- -1 sulfonylureas Chemical class 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 14
- 239000002775 capsule Substances 0.000 description 10
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 10
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000005056 compaction Methods 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940123208 Biguanide Drugs 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000004283 biguanides Chemical class 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 239000013066 combination product Substances 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000004513 sizing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 3
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 3
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- 229940127555 combination product Drugs 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
- 239000000859 incretin Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940051164 ferric oxide yellow Drugs 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000004280 healthy diet Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000030558 renal glucose absorption Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 102000034534 Cotransporters Human genes 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- UUAGGCIRJYEZQD-UHFFFAOYSA-N acetic acid;1,2-dichloroethane Chemical class CC(O)=O.ClCCCl UUAGGCIRJYEZQD-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012802 pre-warming Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229920003179 starch-based polymer Polymers 0.000 description 1
- 239000004628 starch-based polymer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Definitions
- the present invention relates to pharmaceutical composition
- pharmaceutical composition comprising Remogliflozin or pharmaceutically acceptable salt, ester or derivatives thereof in combination with one or more anti-hyperglycemic agent or anti-diabetic agent.
- pharmaceutical composition comprising combination of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin for the treatment of diabetes mellitus.
- the invention also provides processes of preparation of the said compositions and methods of use thereof.
- Type 1 diabetes is a metabolic syndrome characterized by hyperglycemia, which results from an absolute deficiency in insulin secretion (type 1 diabetes) or from resistance to insulin action combined with an inadequate compensatory increase in insulin secretion (type 2 diabetes).
- Type 1 diabetes is also called insulin-dependent diabetes. It used to be called juvenile-onset diabetes, because it often begins in childhood. By far, the most common form of diabetes is type 2 diabetes, accounting for 95% of diabetes cases in adults. Type 2 diabetes is often a milder form of diabetes than type 1. Nevertheless, type 2 diabetes can still cause major health complications, particularly in the smallest blood vessels in the body that nourish the kidneys, nerves, and eyes.
- the chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels.
- Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision.
- Management concentrates on keeping blood sugar levels as close to normal, without causing low blood sugar. This can usually be accomplished with a healthy diet, exercise, weight loss, and use of appropriate medications.
- Oral therapeutic options for the treatment of type 2 diabetes mellitus include agents known as: biguanides (Metformin), sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors.
- Sodium-glucose cotransporter-2 is a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. Sodium-glucose Cotransporter-2 is the major cotransporter involved in glucose reabsorption in the kidney. Sodium-glucose cotransporter-2 inhibitors lead to a reduction in blood glucose levels. Therefore, Sodium-glucose cotransporter- 2 inhibitors have potential use in the treatment of type 2 diabetes.
- Remogliflozin etabonate is the pro-drug of Remogliflozin.
- Remogliflozin etabonate also known as 5-methyl-4-[4-(l -methyl ethoxy )benzyl]-l-(l -methyl ethyl)- lH-pyrazol-3-yl-6-0- (ethoxycarbonyl )-b -D-glucopyranoside has the following formula Also known as 3-(6-0-ethoxycarbonyl-.p.-D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl) methyl]- l-isopropyl-5-methylpyrazole.
- Salts of compounds of formula are useful as the active ingredient in the pharmaceutical presentation of the invention. Such salts may be as described in U.S Patent 7,084,123, herein incorporated by reference.
- Remogliflozin etabonate has the potential to be used as monotherapy for the treatment of diabetes mellitus type 2.
- Remogliflozin etabonate or a salt thereof may be used in combination with another antihyperglycemic agent and/or a hypolipidemic agent and/or antiobesity agent which may be administered orally in the same dosage form in accordance with the invention.
- the other antihyperglycemic agent may be an oral antihyperglycemic agent including biguanides, sulfonylureas, thiazolidinediones, Dipeptidyl peptidase IV inhibitors (DPPIV inhibitor) and alpha-glucosidase inhibitors
- biguanide such as Metformin or other known biguanides that improve hyperglycemia primarily through suppression of hepatic glucose production.
- Metformin is known as N,N-Dimethylimidodicarbonimidic diamide represented by formula Dipeptidyl peptidase IV inhibitors, also known as gliptins, are a class of oral diabetes drugs that inhibit the enzyme dipeptidyl peptidase IV inhibitors which destroys hormone incretin. Incretin helps the body - to regulate insulin secretion and glucose metabolism.
- Gliptins inhibit the inactivation of glucagon-like peptide 1 and gastric inhibitory polypeptide by dipeptidyl peptidase IV inhibitors, allowing glucagon-like peptide 1 and gastric inhibitory polypeptide to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
- dipeptidyl peptidase IV inhibitors is very well known in the art, however recently it has been found that some dipeptidyl peptidase IV inhibitors were also able to provide benefit for refractory cases of abnormal accumulation of liver lipids.
- Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase- 4 (DPP-4) inhibitor class of drugs.
- Vildagliptin is known as (S)-l-[N-(3 -hydroxy- 1- adamantyl)glycyl] pyrrolidine-2-carbonitrile and represented by formula:
- W02001016147 discloses the Remogliflozin base whereas W02002053573 discloses the Remogliflozin etabonate.
- the international patent application W02020089760 discloses the fixed dose pharmaceutical composition comprising combination of Remogliflozin or salt or ester thereof and Vildagliptin or salt thereof in a weight ratio of 1 :0.1 to 1 : 10 for the treatment of diabetes.
- None of the prior arts discloses a composition comprising combination of Remogliflozin or its salt or ester, Vildagliptin or its salt or ester and Metformin. Further the prior art doesn’t disclose a bilayer tablets comprising first layer of Remogliflozin or salt or ester thereof and Metformin hydrochloride and second layer of Vildagliptin or its salt or ester.
- Remogliflozin which is a stable, competitive, reversible and selective inhibitor of sodium- glucose cotransporter-2 inhibits renal glucose reabsorption, promotes urinary glucose excretion and lowers hyperglycemia independently of insulin secretion or action
- Metformin acts by inhibiting gluconeogenesis and glycogenolysis, increase insulin sensitivity in muscles, and delays intestinal glucose absorption (Glucophage summary of product characteristics)
- Vildagliptin acts by rapid and complete inhibition of dipeptidyl peptidase IV inhibitors activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide (Galvus summary of product characteristics).
- Remogliflozin, Vildagliptin and Metformin have low potential for hypoglycaemia, allowing for maximizing glucose lowering benefits without fear of hypoglycaemia.
- the combination also has potential
- Inventors of the present patent application has surprisingly and unexpectedly developed a versatile and robust formulation and manufacturing process that is suitable to overcome such problems and maintain the stability of each drugs in the composition comprising triple combination of Remogliflozin etabonate, Vildagliptin and Metformin.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin or a pharmaceutically acceptable salts, solvate, ester thereof in combination with Vildagliptin or a pharmaceutically acceptable salts thereof and Metformin or a pharmaceutically acceptable salts thereof for the treatment of diabetes mellitus.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising combination of therapeutically effective amount of Remogliflozin or salts or prodrugs thereof with Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof for the treatment of type 2 diabetes mellitus.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof wherein the Remogliflozin etabonate is present in an amount of about 10 mg to about 1000 mg.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Metformin is present in an amount of about 100 mg to about 2500 mg.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein Vildagliptin is present in an amount of about 5 mg to about 500 mg.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin wherein the Remogliflozin etabonate is present in an amount of 100 mg or 250 mg, Vildagliptin is present in an amount of about 25 mg or about 50 mg and metformin hydrochloride is present in an amount of 500 mg or 1000 mg.
- the solid oral pharmaceutical composition can be a tablet or capsule. Particularly the triple combination as per the invention is available in the form of bilayer tablet, wherein the first layer comprises Remogliflozin etabonate and Metformin HC1 and second layer comprises vildagliptin.
- the composition can be administered in single or divided doses.
- bilayer tablets comprising the combination 3 actives as per the invention, the first layer comprising Remogliflozin etabonate and Metformin hydrochloride prepared by wet granulation method and the second layer comprising Vildagliptin is prepared by using dry granulation or direct compression method.
- the solid oral pharmaceutical composition is administered once or twice daily in a single or divided doses to achieve the glycemic control in patient suffering from type 2 diabetes mellitus.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, present in immediate release or controlled release composition.
- composition comprises blend of granules of active ingredients with pharmaceutically acceptable excipients filled in capsule or compressed into a tablets.
- the present invention relates to a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is a bilayer tablet.
- the triple combination product of the present invention has surprisingly similar properties of the original mono or dual combination reference product with reference to dissolution rates and stability.
- the combination formulation prevents an excessive degradation of the mono components and therefore contributes to a better stability of the final triple combination product. Therefore, it is not necessary to somehow adjust the storage limits of the triple combination product.
- Composition of the present invention has not only overcome the manufacturing process difficulties encountered while developing a combination formulation, the manufacturing process of the present invention is also simple and cost-effective which allows easy laboratory testing and that limits the potential of interactions of one drug with other or with one or more excipients used in the formulation.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is stable at 30°C ⁇ 2°C & 75% RH ⁇ 5 % RH.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is stable at 40°C ⁇ 2°C & 75% RH ⁇ 5 % RH.
- the pharmaceutical compositions disclosed herein can be administered to mammalian subjects, preferably humans, for the treatment of type 2 diabetes, impaired glucose tolerance, insulin resistance, and diabetic complications such as hyperglycemia, hyperinsulinemia, and obesity.
- an excipient includes a single excipient as well as two or more different excipients, and the like.
- the term "about” is used synonymously with the term “approximately.”
- the use of the term “about” with regard to a certain therapeutically effective pharmaceutical dose indicates that values slightly outside the cited values, e.g., plus or minus 0.1% to 10%, which are also effective and safe.
- Remogliflozin refers to Remogliflozin, its salts, hydroxylated forms, hydrates, solvates, polymorphic forms, analogs, derivatives, esters, complex, cocrystals, cogeners and prodrugs thereof.
- Remogliflozin etabonate or a pharmaceutically acceptable salt thereof such as the hydrochloride, all of which are collectively referred to as Remogliflozin etabonate.
- Metformin refers to Metformin, its salts, hydroxylated forms, hydrates, solvates, polymorphic forms, analogs, derivatives, esters, complex, cocrystals, cogeners and prodrugs thereof, all of which are collectively referred to as Metformin.
- Vildagliptin refers to Vildagliptin, its salts, hydroxylated forms, hydrates, solvates, polymorphic forms, analogs, derivatives, esters, complex, cocrystals, cogeners and prodrugs thereof, all of which are collectively referred to as Vildagliptin.
- immediate release used throughout the specification means the drug to dissolve in the gastrointestinal contents, with no intention of delaying or prolonging dissolution or absorption of drug.
- effective amount or “therapeutically effective amount” denotes an amount of an active ingredient that, when administered to a subject for treating metabolic disorders, produces an intended therapeutic benefit in a subject.
- active ingredient (used interchangeably with “active” or “active substance” or “drug”) as used herein includes Remogliflozin etabonate and Metformin or pharmaceutically acceptable salts thereof.
- treating also covers the prophylaxis, mitigation, prevention, amelioration, or suppression of a disorder modulated by Remogliflozin etabonate and Metformin in a mammal.
- patient includes mammals like human and other animals.
- the patient is a human.
- pharmaceutically acceptable excipients any of the components of a pharmaceutical composition other than the actives and which are approved by regulatory authorities or are generally regarded as safe for human or animal use.
- combination includes administration of one or more active pharmaceutical ingredients either in a single dosage form or in separate dosage forms; in fixed dose combination or administered separately as adjuvant therapy.
- Diabetes is a metabolic syndrome characterized by hyperglycemia, which results from an absolute deficiency in insulin secretion (type 1 diabetes) or from resistance to insulin action combined with an inadequate compensatory increase in insulin secretion (type 2 diabetes).
- diabetes as employed herein refers to type 2 diabetes and type 1 diabetes, usually type 2 diabetes. Management of diabetes concentrates on keeping blood sugar levels as close to normal, without causing low blood sugar. This can usually be accomplished with a healthy diet, exercise, weight loss, and use of appropriate medications.
- Oral therapeutic options for the treatment of type 2 diabetes mellitus include agents known as: sodium -glucose cotransporter-2 inhibitors, dipeptidyl peptidase IV inhibitors, biguanides (Metformin), sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors.
- the use of the Remogliflozin etabonate or salt thereof in combination with another anti- hyperglycemic agent may be of particular use in achieving anti-hyperglycemic results compared to each of these medicaments alone and greater than the combined additive anti-hyperglycemic effects produced by these medicaments.
- the present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin or a pharmaceutically acceptable salts, solvate, ester thereof in combination with Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof for the treatment of diabetes mellitus.
- the solid oral pharmaceutical composition comprising combination of therapeutically effective amount of Remogliflozin or salts or prodrugs thereof with Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof for the treatment of type 2 diabetes mellitus.
- the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Remogliflozin etabonate is present in an amount of about 10 mg to about 1000 mg.
- the Remogliflozin etabonate is present in an amount of about 100 mg or about 250 mg, more preferably in an amount of about 100 mg.
- the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Metformin ormin is present in an amount of about 100 mg to about 2500 mg.
- Metformin or a pharmaceutically acceptable salts thereof is Metformin hydrochloride.
- Metformin hydrochloride is present in an amount of about 500 mg or about 1000 mg.
- the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Vildagliptin is present in an amount of about 5 mg to about 500 mg.
- Vildagliptin or a pharmaceutically acceptable salts thereof is Vildagliptin base.
- Vildagliptin is present in an amount of about 25 mg or about 100 mg, more preferably in an amount of about 50 mg.
- the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the Remogliflozin etabonate is present in an amount of about 100 mg, wherein the Metformin hydrochloride is present in an amount of about 500 mg, and wherein the Vildagliptin is present in an amount of about 50 mg.
- the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the Remogliflozin etabonate is present in an amount of about 100 mg, wherein the Metformin hydrochloride is present in an amount of about 1000 mg, and wherein the Vildagliptin is present in an amount of about 50 mg.
- a weight ratio of Remogliflozin etabonate and Metformin hydrochloride ranges from about 1 : 1 to about 1 : 15. In still another embodiment, the weight ratio of Remogliflozin etabonate and Metformin hydrochloride is about 1:5 or about 1:10.
- a weight ratio of Remogliflozin etabonate and Vildagliptin ranges from about 1:0.1 to about 1:1. In still another embodiment, the weight ratio of Remogliflozin etabonate and Vildagliptin is about 1:0.25 or about 1:0.5.
- a weight ratio of Vildagliptin and Metformin hydrochloride ranges from about 1 : 10 to about 1 :30. In still another embodiment, the weight ratio of Vildagliptin and Metformin hydrochloride is about 1:10 or about 1:20.
- the weight ratio of Remogliflozin etabonate: Vildagliptin: Metformin hydrochloride is about 1:0.5:5 or about 1:0.5:10.
- the dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.
- the composition can be administered in single or divided doses.
- the dosage form of the present invention may be in form of a tablet, capsule, granules, tablet in tablet, pellets, beads, tablets in capsule, granules/pellets in capsule, bilayer tablet, trilayer tablet, inlay tablet, caplet, dry syrup or suspension.
- the solid oral pharmaceutical composition is tablet or capsule, particularly is the tablet, wherein the tablet can be coated or uncoated.
- the triple combination as per the invention may available in the form of capsule wherein a capsule may comprise coated or uncoated granules or pellets of three active ingredients.
- the solid oral pharmaceutical composition is administered once or twice daily in a single or divided doses to achieve the glycemic control in patient suffering from type 2 diabetes mellitus.
- composition comprises blend of granules of active ingredients with pharmaceutically acceptable excipients filled in capsule or compressed in tablets.
- solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is tablet and Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin are mixed together and present in core of the compressed tablet.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the composition is a multilayer tablet.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein Remogliflozin etabonate and Vildagliptin present in different layers.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein metformin hydrochloride is present in the layer comprising Remogliflozin etabonate.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein Metformin hydrochloride is present in the layer comprising vildagliptin.
- the said pharmaceutical composition is the immediate release bilayer tablets composition comprising Remogliflozin or pharmaceutically acceptable salt or ester thereof, Metformin or pharmaceutically acceptable salt thereof, Vildagliptin and pharmaceutical acceptable excipients.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein Remogliflozin etabonate and Metformin hydrochloride are mixed together in one layer and Vildagliptin is present in second layer.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using wet granulation or dry granulation or direct compression method.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Vildagliptin comprising layer is prepared using dry granulation or direct compression method.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using wet granulation method and granules of Vildagliptin comprising layer is prepared using direct compression method.
- the solid oral pharmaceutical composition is the trilayer tablet and Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin are present in each layer of the tablet.
- the solid oral pharmaceutical composition is the trilayer tablet, wherein Remogliflozin etabonate and Metformin hydrochloride are present in same layer, Vildagliptin is present in separate layer and third layer is drug free layer.
- the solid oral pharmaceutical composition comprising
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition.
- the tablets can be coated or uncoated wherein the coating can be functional or film coating. Alternatively there may present the barrier layer between two layers comprising active ingredients.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein the composition is coated with aqueous or non-aqueous film coating.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein the composition is coated with aqueous film coating.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein the composition is coated with non-aqueous film coating.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin release not less than 70 % of the labeled amount within 45 minutes.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin release not less than 90 % of the labeled amount within 45 minutes.
- the solid oral pharmaceutical composition comprising
- Remogliflozin etabonate, metformin hydrochloride and Vildagliptin is immediate release composition, wherein Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin release not less than 95 % of the labeled amount within 45 minutes.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the composition comprises one or more excipients.
- the excipients may include rate controlling polymers or non-polymers, diluents, disintegrants, binders, bulking agents, anti-oxidants, buffering agents, colorants, flavoring agents, coating agents such as opadry white, anti-tacking agents, emulsifiers, surfactants, plasticizers, stabilizers, preservatives, lubricants, glidants, chelating agents and the like used either alone or in combination thereof.
- rate controlling polymers or non-polymers diluents, disintegrants, binders, bulking agents, anti-oxidants, buffering agents, colorants, flavoring agents, coating agents such as opadry white, anti-tacking agents, emulsifiers, surfactants, plasticizers, stabilizers, preservatives, lubricants, glidants, chelating agents and the like used either alone or in combination thereof.
- composition comprises blend of granules of active ingredients with pharmaceutically acceptable excipients filled in capsule or compressed in tablets.
- Non-limiting examples of diluents include anhydrous lactose, microcrystalline cellulose, silicified microcrystalline cellulose (e.g., Prosolv®), microfme cellulose, hydroxy propyl cellulose, lactose, starch, pregelatinized starch, mannitol, sorbitol, dextrates, dextrin, maltodextrin, dextrose, calcium carbonate, calcium sulfate, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide, sugars such as dextrose, mannitol, low substituted hydroxy propyl cellulose, sorbitol, or sucrose and combinations thereof.
- the diluents according to current invention are present in an amount 5- 50% w/w.
- Non limiting examples of disintegrants suitable for use herein include, crosscarmellose sodium, starch, potato starch, corn starch, crospovidone, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants.
- disintegrant include, crosscarmellose sodium, starch, potato starch, corn starch, crospovidone, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants.
- crospovidone XL- 10 any grade of crospovidone can be used, including for example crospovidone XL- 10, and includes members selected from the group consisting of Kollidon CL.RTM., Polyplasdone XL.RTM., Kollidon CL-M.RTM., Polyplasdone XL-10.RTM., and Polyplasdone INF- 10.RTM.
- the disintegrant, if present, of the stock granulation is sodium starch glycolate, croscarmellose sodium and/or crospovidone.
- These materials are also referred to as insoluble polyvidone, insoluble polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone, and polyvinylpyrrolidone-P.
- the crospovidone can be substituted with croscarmellose sodium, sodium starch glycolate.
- the disintegrant according to current invention are present in an amount 1-30% w/w.
- Non-limiting examples of glidants and lubricants include one or more of stearic acid, magnesium stearate, talc, colloidal silicon dioxide, and sodium stearyl fumarate.
- the glidant according to current invention are present in an amount 0.05-5% w/w.
- Non limiting examples of binder include low substituted hydroxy propyl cellulose, Hydroxy propyl cellulose, starches, pregelatinize starches, gelatin, polyvinylpyrrolidone, povidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, hydroxypropyl methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch.
- the binder according to current invention are present in an amount 0.1-20% w/w.
- Non-limiting examples of preservatives include one or more of phenoxy ethanol, parabens such as methyl paraben and propyl paraben and their sodium salts, propylene glycols, sorbates, urea derivatives such as diazolindinyl urea, and mixtures thereof.
- Non-limiting examples of buffering agents include sodium hydroxide, potassium hydroxide, ammonium hydroxide and mixtures thereof.
- Non-limiting examples of chelating agents include ethylene diamine tetraacetic acid (“EDTA”), and disodium edetate and EDTA derivatives.
- the preservatives according to current invention are present in an amount 0.1-10% w/w.
- Suitable plasticizers include, but are not limited to, one or more of diethyl phthalate, triethyl citrate, acetyl tributyl citrate, dibutyl phthalate, triacetin, propylene glycol, and polyethylene glycol.
- the solvents comprise one or more of dichloromethane, acetone, ethanol, methanol, isopropyl alcohol, water or mixture thereof.
- Suitable rate controlling polymers are selected from, but not limited to, methacrylic acid copolymer dispersion, polyvinylpyrrolidone (PVP) and its derivatives such as copolyvidone, mixtures of PVP and polyvinylacetates, such as Kollidon SR; cellulosic polymers such as hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose; vinyl acetate copolymers; polysaccharides (such as alginate, xanthan gum, guar gum etc.), starch and starch-based polymers, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives and mixtures thereof.
- Suitable rate controlling non-polymers includes, but not limited to fat, wax, fatty acid, fatty acid ester, long chain monohydric alcohol or their ester or any combinations thereof.
- Non-limiting examples of solvents include one or more of water; tetrahydrofuran; alcohols, e.g., methanol, ethanol, isopropyl alcohol and higher alcohols; alkanes, e.g., pentane, hexane and heptane; ketones, e.g., acetone and methyl ethyl ketone; chlorinated hydrocarbons, e.g., chloroform, carbon tetrachloride, methylene chloride and ethylene dichloride acetates, e.g., ethyl acetate.
- alcohols e.g., methanol, ethanol, isopropyl alcohol and higher alcohols
- alkanes e.g., pentane, hexane and heptane
- ketones e.g., acetone and methyl ethyl ketone
- chlorinated hydrocarbons e.g., chloro
- Suitable lubricants include stearic acid, magnesium stearate, sodium stearyl fumarate, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, zinc stearate, calcium stearate, silica, talc, polyethylene glycol, paraffin or the mixtures thereof.
- the lubricant according to current invention are present in an amount 0.1- 10% w/w.
- Suitable anti-tacking agents may be selected from stearates; stearic acid; vegetable oil; waxes; a blend of magnesium stearate and sodium lauryl sulfate; sodium benzoate; sodium acetate and the like.
- the surfactants and emulsifiers may be ionic or nonionic. Specific examples of surfactants and emulsifiers are such as poloxamers, polyethylene glycols, polyethylene glycol monostearate, polysorbates, sodium lauryl sulfate, polyethoxylated and hydrogenated castor oil, etc.
- the composition of the present invention may include stabilizers like gums, agar; taste masking agents like acrylic polymers, copolymers of acrylates, celluloses, resins; coloring agents like titanium dioxide, natural food colors, dyes suitable for food, drug and cosmetic applications.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using wet granulation method and granules of Vildagliptin comprising layer is prepared using dry granulation method.
- granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using following steps: i. Mix Remogliflozin etabonate, Metformin, diluent & disntigrant ii. Separately prepared binder solution. iii. Granulate mixture of step (i) using binder solution of step (ii). iv. Dry the wet granules of step (iii). v. Mix the extra-granular excipients i.e. disintegrant and lubricant with dry granules of step
- granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using following steps: i. Mix Remogliflozin etabonate, Metformin and L- hydroxypropyl cellulose. ii. Separately prepared binder solution by mixing hydroxyl propyl cellulose with water. iii. Granulate mixture of step (i) using binder solution of step (ii). iv. Dry the wet granules of step (iii). v. Mix L- hydroxypropyl cellulose extra granularly with dry granules of step (iv) and finally add magnesium stearate.
- granules of Vildagliptin comprising layer is prepared using roller compaction process.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein composition is packed in Alu- Alu blister pack.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the composition is stable at 30°C ⁇ 2°C & 75% RH ⁇ 5 % RH.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is stable at 40°C ⁇ 2°C & 75% RH ⁇ 5 % RH.
- the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein composition exhibits a synergistic effect.
- compositions disclosed herein can be administered to mammalian subjects, preferably humans, for the treatment of type 2 diabetes, impaired glucose tolerance, insulin resistance, and diabetic complications such as hyperglycemia, hyperinsulinemia, and obesity.
- EXAMPLE 1 Fixed dose combination of Remogliflozin etabonate, Vildagliptin and Metformin hydrochloride.
- Part III Coating Part
- step 6.1 Remove granules of step 6.1 and Mix manually in polybag with sifted L-hydroxy propyl cellullose from step no 6.1 and sift through # 16
- Step 6.5 Remove blend from blender (Step 6.3) and Mix manually in double polybag with sifted magnesium stearate (Step 6.4) & Sift through # 16 sieve and add to blender (of step 6.4) and Mix for 3 minutes at 12 rpm.
- Granules quantity is more than 70% of practical weight then proceed for Lubrication, if granules quantity is less than 70% proceed for next roll compaction cycle & sizing using fines.
- step 4.1 Remove blend from step 4.1 and Mix with sifted magnesium stearate from step 4.2 and Sift through #30 sieve and Load to blender (step 4.1) and Mix for 3 minute.
- step 1.3 Pass the color dispersion from step 1.2 through colloid mill for approximately 5 to 15 minutes. Rinse the colloid mill using Methylene chloride and Isopropyl alcohol mixture from step 1.1 and filter it through #200 mesh Nylon cloth.
- Example 3 Dissolution data of composition of examples 1 & 2 I) Dissolution data for Remogliflozin etabonate and Vildagliptin:
- Dissolution data Dissolution data:
- Example 4 Stability data of composition of Example 1 Condition: 30°C ⁇ 2°C & 75% RH ⁇ 5 % RH
- Example 5 Stability data of composition of example 2 Storage condition: 30°C ⁇ 2°C & 75% RH ⁇ 5 % RH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to pharmaceutical composition comprising Remogliflozin or pharmaceutically acceptable salt, ester or derivatives thereof in combination with one or more anti-hyperglycemic agent. In particular, the present invention relates to pharmaceutical composition comprising combination of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin for the treatment of diabetes mellitus and its method of manufacturing thereof.
Description
PHARMACUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN ETABONATE, METFORMIN HYDROCHLORIDE AND VILDAGLIPTIN
RELATED APPLICATION
This application claims the benefit of Indian Provisional Patent Application No. 202121026505 filed on June 14, 2021, the entire disclosure of which is incorporated by reference herein.
FIELD OF THE INVENTION
The present invention relates to pharmaceutical composition comprising Remogliflozin or pharmaceutically acceptable salt, ester or derivatives thereof in combination with one or more anti-hyperglycemic agent or anti-diabetic agent. Particularly the present invention relates to pharmaceutical composition comprising combination of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin for the treatment of diabetes mellitus. The invention also provides processes of preparation of the said compositions and methods of use thereof.
BACKGROUND OF THE INVENTION
Diabetes is a metabolic syndrome characterized by hyperglycemia, which results from an absolute deficiency in insulin secretion (type 1 diabetes) or from resistance to insulin action combined with an inadequate compensatory increase in insulin secretion (type 2 diabetes). Type 1 diabetes is also called insulin-dependent diabetes. It used to be called juvenile-onset diabetes, because it often begins in childhood. By far, the most common form of diabetes is type 2 diabetes, accounting for 95% of diabetes cases in adults. Type 2 diabetes is often a milder form of diabetes than type 1. Nevertheless, type 2 diabetes can still cause major health complications, particularly in the smallest blood vessels in the body that nourish the kidneys, nerves, and eyes. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. Management concentrates on keeping blood sugar levels as close to normal, without causing low blood sugar. This can usually be accomplished with a healthy diet, exercise, weight loss, and use of appropriate medications. Oral therapeutic options for the treatment of type 2 diabetes mellitus include agents known as: biguanides (Metformin), sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors. These agents are all indicated as monotherapy and some are indicated for use in combination therapy, generally, after monotherapy has been found to be inadequate.
Sodium-glucose cotransporter-2 is a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. Sodium-glucose Cotransporter-2 is the major cotransporter involved in glucose reabsorption in the kidney. Sodium-glucose cotransporter-2 inhibitors lead to a reduction in blood glucose levels. Therefore, Sodium-glucose cotransporter- 2 inhibitors have potential use in the treatment of type 2 diabetes.
Remogliflozin etabonate is the pro-drug of Remogliflozin. Remogliflozin etabonate also known as 5-methyl-4-[4-(l -methyl ethoxy )benzyl]-l-(l -methyl ethyl)- lH-pyrazol-3-yl-6-0- (ethoxycarbonyl )-b -D-glucopyranoside has the following formula
Also known as 3-(6-0-ethoxycarbonyl-.p.-D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl) methyl]- l-isopropyl-5-methylpyrazole. Salts of compounds of formula are useful as the active ingredient in the pharmaceutical presentation of the invention. Such salts may be as described in U.S Patent 7,084,123, herein incorporated by reference. Remogliflozin etabonate has the potential to be used as monotherapy for the treatment of diabetes mellitus type 2. Remogliflozin etabonate or a salt thereof may be used in combination with another antihyperglycemic agent and/or a hypolipidemic agent and/or antiobesity agent which may be administered orally in the same dosage form in accordance with the invention. The other antihyperglycemic agent may be an oral antihyperglycemic agent including biguanides, sulfonylureas, thiazolidinediones, Dipeptidyl peptidase IV inhibitors (DPPIV inhibitor) and alpha-glucosidase inhibitors Particularly the combination comprises a biguanide such as Metformin or other known biguanides that improve hyperglycemia primarily through suppression of hepatic glucose production.
Metformin is known as N,N-Dimethylimidodicarbonimidic diamide represented by formula
Dipeptidyl peptidase IV inhibitors, also known as gliptins, are a class of oral diabetes drugs that inhibit the enzyme dipeptidyl peptidase IV inhibitors which destroys hormone incretin. Incretin helps the body - to regulate insulin secretion and glucose metabolism. Gliptins inhibit the
inactivation of glucagon-like peptide 1 and gastric inhibitory polypeptide by dipeptidyl peptidase IV inhibitors, allowing glucagon-like peptide 1 and gastric inhibitory polypeptide to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. The use of dipeptidyl peptidase IV inhibitors is very well known in the art, however recently it has been found that some dipeptidyl peptidase IV inhibitors were also able to provide benefit for refractory cases of abnormal accumulation of liver lipids.
Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase- 4 (DPP-4) inhibitor class of drugs. Vildagliptin is known as (S)-l-[N-(3 -hydroxy- 1- adamantyl)glycyl] pyrrolidine-2-carbonitrile and represented by formula:
International Patent Application No. W02001016147 discloses the Remogliflozin base whereas W02002053573 discloses the Remogliflozin etabonate.
Furthermore, U.S. Patent No. 6,166,063 discloses Vildagliptin;
The international patent application W02020089760 discloses the fixed dose pharmaceutical composition comprising combination of Remogliflozin or salt or ester thereof and Vildagliptin or salt thereof in a weight ratio of 1 :0.1 to 1 : 10 for the treatment of diabetes.
International patent application W02020089761 discloses the stable pharmaceutical composition comprising a first portion and a second portion, wherein said first portion comprises Remogliflozin or salt or ester thereof and a pharmaceutically acceptable excipient, said second portion comprises Vildagliptin or salt thereof and a pharmaceutically acceptable excipient
International patent application W02018/198102 discloses the fixed dose solid oral dosage form comprising Remogliflozin or pharmaceutically acceptable salts thereof in immediate release form and Metformin or its pharmaceutically acceptable salts thereof in an extended release form_with one or more pharmaceutically acceptable excipients.
International patent application W02019/162800 discloses the immediate release pharmaceutical composition comprising Remogliflozin or pharmaceutically acceptable salt or ester thereof and Metformin or pharmaceutically acceptable salt thereof.
None of the prior arts discloses a composition comprising combination of Remogliflozin or its salt or ester, Vildagliptin or its salt or ester and Metformin. Further the prior art doesn’t disclose
a bilayer tablets comprising first layer of Remogliflozin or salt or ester thereof and Metformin hydrochloride and second layer of Vildagliptin or its salt or ester.
The management of diabetes and associated complications often requires combining drugs with supplemental mechanisms of action. The advanced therapy using a combination of two or more drugs having different pharmacological actions makes it possible to improve preventive or therapeutic effects, while lowering side effects arising from the long term administration of a single drug. Therefore, a need for further development of methods of treatment, combination, and pharmaceutical compositions clearly exists. It is further much more user friendly for the patients to take just one a fixed-dose combination product comprising all three active pharmaceutical ingredients: (i) Remogliflozin etabonate or a salt thereof, (ii) a Metformin HC1 and (iii) a Vildagliptin in comparison with separate single-dosed products.
Metformin Additionally, a fixed dose combination of Remogliflozin, Vildagliptin and Metformin will help to simplify the treatment of type 2 diabetes mellitus, reduce the pill burden and consequently improve compliance. Remogliflozin, Vildagliptin and Metformin have different glycemic reduce parameters e.g. Remogliflozin which is a stable, competitive, reversible and selective inhibitor of sodium- glucose cotransporter-2 inhibits renal glucose reabsorption, promotes urinary glucose excretion and lowers hyperglycemia independently of insulin secretion or action (Remogliflozin summary of product characteristics), Metformin acts by inhibiting gluconeogenesis and glycogenolysis, increase insulin sensitivity in muscles, and delays intestinal glucose absorption (Glucophage summary of product characteristics), whereas Vildagliptin acts by rapid and complete inhibition of dipeptidyl peptidase IV inhibitors activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide (Galvus summary of product characteristics). In addition, Remogliflozin, Vildagliptin and Metformin have low potential for hypoglycaemia, allowing for maximizing glucose lowering benefits without fear of hypoglycaemia. The combination also has potential for moderate weight loss.
While combining two or more antidiabetic drugs in a single composition provides patient compliance, but on the other end it is also highly challenging for a formulator, because each drug has different physical and chemical properties, and hence maintaining the in-process parameters as well as avoiding manufacturing problems like sticking and clogging is always challenging for a formulator. Moreover, maintaining drugs’ properties in the finished product like dissolution, stability, impurity profile, etc. are also highly challenging. Combining three drugs is even more challenging than combination of two drugs. Inventors of the present patent
application has surprisingly and unexpectedly developed a versatile and robust formulation and manufacturing process that is suitable to overcome such problems and maintain the stability of each drugs in the composition comprising triple combination of Remogliflozin etabonate, Vildagliptin and Metformin.
SUMMARY OF THE INVENTION
The present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin or a pharmaceutically acceptable salts, solvate, ester thereof in combination with Vildagliptin or a pharmaceutically acceptable salts thereof and Metformin or a pharmaceutically acceptable salts thereof for the treatment of diabetes mellitus.
In one aspect, the present invention relates to a solid oral pharmaceutical composition comprising combination of therapeutically effective amount of Remogliflozin or salts or prodrugs thereof with Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof for the treatment of type 2 diabetes mellitus.
In another aspect, the present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof wherein the Remogliflozin etabonate is present in an amount of about 10 mg to about 1000 mg.
In another aspect, the present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Metformin is present in an amount of about 100 mg to about 2500 mg.
In another aspect, the present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein Vildagliptin is present in an amount of about 5 mg to about 500 mg.
In another aspect, the present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin wherein the Remogliflozin etabonate is present in an amount of 100 mg or 250 mg, Vildagliptin is present in an amount of about 25 mg or about 50 mg and metformin hydrochloride is present in an amount of 500 mg or 1000 mg.
In another aspect, the solid oral pharmaceutical composition can be a tablet or capsule. Particularly the triple combination as per the invention is available in the form of bilayer tablet, wherein the first layer comprises Remogliflozin etabonate and Metformin HC1 and second layer comprises vildagliptin. The composition can be administered in single or divided doses.
The bilayer tablets comprising the combination 3 actives as per the invention, the first layer comprising Remogliflozin etabonate and Metformin hydrochloride prepared by wet granulation method and the second layer comprising Vildagliptin is prepared by using dry granulation or direct compression method.
In another aspect, the solid oral pharmaceutical composition is administered once or twice daily in a single or divided doses to achieve the glycemic control in patient suffering from type 2 diabetes mellitus.
In another aspect, the present invention relates to a solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, present in immediate release or controlled release composition.
Further the composition comprises blend of granules of active ingredients with pharmaceutically acceptable excipients filled in capsule or compressed into a tablets.
In another aspect, the present invention relates to a solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is a bilayer tablet.
The triple combination product of the present invention has surprisingly similar properties of the original mono or dual combination reference product with reference to dissolution rates and stability. The combination formulation prevents an excessive degradation of the mono components and therefore contributes to a better stability of the final triple combination product. Therefore, it is not necessary to somehow adjust the storage limits of the triple combination product. Composition of the present invention has not only overcome the manufacturing process difficulties encountered while developing a combination formulation, the manufacturing process of the present invention is also simple and cost-effective which allows easy laboratory testing and that limits the potential of interactions of one drug with other or with one or more excipients used in the formulation.
In another aspect, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is stable at 30°C ± 2°C & 75% RH ± 5 % RH.
In another aspect, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is stable at 40°C ± 2°C & 75% RH ± 5 % RH.
According to embodiments of the present invention, the pharmaceutical compositions disclosed herein can be administered to mammalian subjects, preferably humans, for the treatment of type 2 diabetes, impaired glucose tolerance, insulin resistance, and diabetic complications such as hyperglycemia, hyperinsulinemia, and obesity.
DETAILED DESCRIPTION OF THE INVENTION The terms used herein are defined as follows. If a definition set forth in the present application and a definition set forth later in a non-provisional application claiming priority from the present provisional application are in conflict, the definition in the non-provisional application shall control the meaning of the terms.
The term singular forms "a," "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "an excipient" includes a single excipient as well as two or more different excipients, and the like.
As used herein, the term "about" is used synonymously with the term "approximately." Illustratively, the use of the term "about" with regard to a certain therapeutically effective pharmaceutical dose indicates that values slightly outside the cited values, e.g., plus or minus 0.1% to 10%, which are also effective and safe.
The term Remogliflozin refers to Remogliflozin, its salts, hydroxylated forms, hydrates, solvates, polymorphic forms, analogs, derivatives, esters, complex, cocrystals, cogeners and prodrugs thereof. Remogliflozin etabonate or a pharmaceutically acceptable salt thereof such as the hydrochloride, all of which are collectively referred to as Remogliflozin etabonate.
The term Metformin refers to Metformin, its salts, hydroxylated forms, hydrates, solvates, polymorphic forms, analogs, derivatives, esters, complex, cocrystals, cogeners and prodrugs thereof, all of which are collectively referred to as Metformin.
The term Vildagliptin refers to Vildagliptin, its salts, hydroxylated forms, hydrates, solvates, polymorphic forms, analogs, derivatives, esters, complex, cocrystals, cogeners and prodrugs thereof, all of which are collectively referred to as Vildagliptin.
The term "immediate release (IR)" used throughout the specification means the drug to dissolve in the gastrointestinal contents, with no intention of delaying or prolonging dissolution or absorption of drug.
The term "effective amount" or "therapeutically effective amount" denotes an amount of an active ingredient that, when administered to a subject for treating metabolic disorders, produces an intended therapeutic benefit in a subject.
The term “active ingredient” (used interchangeably with “active” or “active substance” or “drug”) as used herein includes Remogliflozin etabonate and Metformin or pharmaceutically acceptable salts thereof.
The term “treating” or “treatment” as used herein also covers the prophylaxis, mitigation, prevention, amelioration, or suppression of a disorder modulated by Remogliflozin etabonate and Metformin in a mammal.
The term "patient" includes mammals like human and other animals. Preferably, the patient is a human.
By “pharmaceutically acceptable excipients”, it is meant any of the components of a pharmaceutical composition other than the actives and which are approved by regulatory authorities or are generally regarded as safe for human or animal use.
The term “combination” includes administration of one or more active pharmaceutical ingredients either in a single dosage form or in separate dosage forms; in fixed dose combination or administered separately as adjuvant therapy.
Throughout this specification it is to be understood that the words "comprise" and "include" and variations such as "comprises", "comprising", "includes", "including" are to be interpreted inclusively, unless the context requires otherwise.
Diabetes is a metabolic syndrome characterized by hyperglycemia, which results from an absolute deficiency in insulin secretion (type 1 diabetes) or from resistance to insulin action combined with an inadequate compensatory increase in insulin secretion (type 2 diabetes). The term "diabetes" as employed herein refers to type 2 diabetes and type 1 diabetes, usually type 2 diabetes. Management of diabetes concentrates on keeping blood sugar levels as close to normal, without causing low blood sugar. This can usually be accomplished with a healthy diet, exercise, weight loss, and use of appropriate medications. Oral therapeutic options for the treatment of type 2 diabetes mellitus include agents known as: sodium -glucose cotransporter-2 inhibitors, dipeptidyl peptidase IV inhibitors, biguanides (Metformin), sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors.
The use of the Remogliflozin etabonate or salt thereof in combination with another anti- hyperglycemic agent may be of particular use in achieving anti-hyperglycemic results compared to each of these medicaments alone and greater than the combined additive anti-hyperglycemic effects produced by these medicaments.
The present invention relates to a solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin or a pharmaceutically acceptable salts, solvate, ester thereof in combination with Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof for the treatment of diabetes mellitus.
In another embodiment, the solid oral pharmaceutical composition comprising combination of therapeutically effective amount of Remogliflozin or salts or prodrugs thereof with Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof for the treatment of type 2 diabetes mellitus.
In another embodiment, the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Remogliflozin etabonate is present in an amount of about 10 mg to about 1000 mg.
In still another embodiment, the Remogliflozin etabonate is present in an amount of about 100 mg or about 250 mg, more preferably in an amount of about 100 mg.
In another embodiment, the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin or a pharmaceutically acceptable salts thereof and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Metformin ormin is present in an amount of about 100 mg to about 2500 mg.
In still another embodiment, Metformin or a pharmaceutically acceptable salts thereof is Metformin hydrochloride.
In still another embodiment, Metformin hydrochloride is present in an amount of about 500 mg or about 1000 mg.
In another embodiment, the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin or a pharmaceutically acceptable salts thereof, wherein the Vildagliptin is present in an amount of about 5 mg to about 500 mg.
In still another embodiment, Vildagliptin or a pharmaceutically acceptable salts thereof is Vildagliptin base.
In still another embodiment, Vildagliptin is present in an amount of about 25 mg or about 100 mg, more preferably in an amount of about 50 mg.
In another embodiment, the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the Remogliflozin etabonate is present in an amount of about 100 mg, wherein the
Metformin hydrochloride is present in an amount of about 500 mg, and wherein the Vildagliptin is present in an amount of about 50 mg.
In another embodiment, the solid oral pharmaceutical composition comprising therapeutically effective amount of Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the Remogliflozin etabonate is present in an amount of about 100 mg, wherein the Metformin hydrochloride is present in an amount of about 1000 mg, and wherein the Vildagliptin is present in an amount of about 50 mg.
In another embodiment, a weight ratio of Remogliflozin etabonate and Metformin hydrochloride ranges from about 1 : 1 to about 1 : 15. In still another embodiment, the weight ratio of Remogliflozin etabonate and Metformin hydrochloride is about 1:5 or about 1:10.
In another embodiment, a weight ratio of Remogliflozin etabonate and Vildagliptin ranges from about 1:0.1 to about 1:1. In still another embodiment, the weight ratio of Remogliflozin etabonate and Vildagliptin is about 1:0.25 or about 1:0.5.
In another embodiment, a weight ratio of Vildagliptin and Metformin hydrochloride ranges from about 1 : 10 to about 1 :30. In still another embodiment, the weight ratio of Vildagliptin and Metformin hydrochloride is about 1:10 or about 1:20.
In preferred embodiment, the weight ratio of Remogliflozin etabonate: Vildagliptin: Metformin hydrochloride is about 1:0.5:5 or about 1:0.5:10.
The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result. In still another embodiment, the composition can be administered in single or divided doses. The dosage form of the present invention may be in form of a tablet, capsule, granules, tablet in tablet, pellets, beads, tablets in capsule, granules/pellets in capsule, bilayer tablet, trilayer tablet, inlay tablet, caplet, dry syrup or suspension.
In still another embodiment, the solid oral pharmaceutical composition is tablet or capsule, particularly is the tablet, wherein the tablet can be coated or uncoated.
The triple combination as per the invention may available in the form of capsule wherein a capsule may comprise coated or uncoated granules or pellets of three active ingredients.
In still another embodiment, the solid oral pharmaceutical composition is administered once or twice daily in a single or divided doses to achieve the glycemic control in patient suffering from type 2 diabetes mellitus.
Further the composition comprises blend of granules of active ingredients with pharmaceutically acceptable excipients filled in capsule or compressed in tablets.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is tablet and Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin are mixed together and present in core of the compressed tablet.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the composition is a multilayer tablet.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein Remogliflozin etabonate and Vildagliptin present in different layers.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein metformin hydrochloride is present in the layer comprising Remogliflozin etabonate. In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein Metformin hydrochloride is present in the layer comprising vildagliptin.
In still another embodiment, the said pharmaceutical composition is the immediate release bilayer tablets composition comprising Remogliflozin or pharmaceutically acceptable salt or ester thereof, Metformin or pharmaceutically acceptable salt thereof, Vildagliptin and pharmaceutical acceptable excipients.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein Remogliflozin etabonate and Metformin hydrochloride are mixed together in one layer and Vildagliptin is present in second layer.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using wet granulation or dry granulation or direct compression method.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Vildagliptin comprising layer is prepared using dry granulation or direct compression method.
In still another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using wet granulation method and granules of Vildagliptin comprising layer is prepared using direct compression method.
In another embodiment, the solid oral pharmaceutical composition is the trilayer tablet and Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin are present in each layer of the tablet.
In still another embodiment, the solid oral pharmaceutical composition is the trilayer tablet, wherein Remogliflozin etabonate and Metformin hydrochloride are present in same layer, Vildagliptin is present in separate layer and third layer is drug free layer.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release or controlled release composition. In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition.
The tablets can be coated or uncoated wherein the coating can be functional or film coating. Alternatively there may present the barrier layer between two layers comprising active ingredients.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein the composition is coated with aqueous or non-aqueous film coating.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein the composition is coated with aqueous film coating.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein the composition is coated with non-aqueous film coating. In still another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin release not less than 70 % of the labeled amount within 45 minutes.
In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is immediate release composition, wherein Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin release not less than 90 % of the labeled amount within 45 minutes. In still another embodiment, the solid oral pharmaceutical composition comprising
Remogliflozin etabonate, metformin hydrochloride and Vildagliptin is immediate release composition, wherein Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin release not less than 95 % of the labeled amount within 45 minutes.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the composition comprises one or more excipients.
The excipients may include rate controlling polymers or non-polymers, diluents, disintegrants, binders, bulking agents, anti-oxidants, buffering agents, colorants, flavoring agents, coating agents such as opadry white, anti-tacking agents, emulsifiers, surfactants, plasticizers, stabilizers, preservatives, lubricants, glidants, chelating agents and the like used either alone or in combination thereof.
Further the composition comprises blend of granules of active ingredients with pharmaceutically acceptable excipients filled in capsule or compressed in tablets.
Non-limiting examples of diluents include anhydrous lactose, microcrystalline cellulose, silicified microcrystalline cellulose (e.g., Prosolv®), microfme cellulose, hydroxy propyl cellulose, lactose, starch, pregelatinized starch, mannitol, sorbitol, dextrates, dextrin, maltodextrin, dextrose, calcium carbonate, calcium sulfate, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide, sugars such as dextrose, mannitol, low substituted hydroxy propyl cellulose, sorbitol, or sucrose and combinations thereof. The diluents according to current invention are present in an amount 5- 50% w/w.
Non limiting examples of disintegrants suitable for use herein include, crosscarmellose sodium, starch, potato starch, corn starch, crospovidone, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants. Several specific types of disintegrant are suitable for use in the compositions described herein. For example, any grade of crospovidone can be used, including for example crospovidone XL- 10, and includes members selected from the group consisting of Kollidon CL.RTM., Polyplasdone XL.RTM., Kollidon CL-M.RTM., Polyplasdone XL-10.RTM., and Polyplasdone INF- 10.RTM. In one embodiment, the disintegrant, if present, of the stock granulation is sodium
starch glycolate, croscarmellose sodium and/or crospovidone. These materials are also referred to as insoluble polyvidone, insoluble polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone, and polyvinylpyrrolidone-P. The crospovidone can be substituted with croscarmellose sodium, sodium starch glycolate. The disintegrant according to current invention are present in an amount 1-30% w/w.
Non-limiting examples of glidants and lubricants include one or more of stearic acid, magnesium stearate, talc, colloidal silicon dioxide, and sodium stearyl fumarate. The glidant according to current invention are present in an amount 0.05-5% w/w.
Non limiting examples of binder include low substituted hydroxy propyl cellulose, Hydroxy propyl cellulose, starches, pregelatinize starches, gelatin, polyvinylpyrrolidone, povidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, hydroxypropyl methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch. The binder according to current invention are present in an amount 0.1-20% w/w.
Non-limiting examples of preservatives include one or more of phenoxy ethanol, parabens such as methyl paraben and propyl paraben and their sodium salts, propylene glycols, sorbates, urea derivatives such as diazolindinyl urea, and mixtures thereof. Non-limiting examples of buffering agents include sodium hydroxide, potassium hydroxide, ammonium hydroxide and mixtures thereof. Non-limiting examples of chelating agents include ethylene diamine tetraacetic acid (“EDTA”), and disodium edetate and EDTA derivatives. The preservatives according to current invention are present in an amount 0.1-10% w/w.
Suitable plasticizers include, but are not limited to, one or more of diethyl phthalate, triethyl citrate, acetyl tributyl citrate, dibutyl phthalate, triacetin, propylene glycol, and polyethylene glycol. The solvents comprise one or more of dichloromethane, acetone, ethanol, methanol, isopropyl alcohol, water or mixture thereof.
Suitable rate controlling polymers are selected from, but not limited to, methacrylic acid copolymer dispersion, polyvinylpyrrolidone (PVP) and its derivatives such as copolyvidone, mixtures of PVP and polyvinylacetates, such as Kollidon SR; cellulosic polymers such as hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose; vinyl acetate copolymers; polysaccharides (such as alginate, xanthan gum, guar gum etc.), starch and starch-based polymers, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives and mixtures thereof.
Suitable rate controlling non-polymers includes, but not limited to fat, wax, fatty acid, fatty acid ester, long chain monohydric alcohol or their ester or any combinations thereof.
Non-limiting examples of solvents include one or more of water; tetrahydrofuran; alcohols, e.g., methanol, ethanol, isopropyl alcohol and higher alcohols; alkanes, e.g., pentane, hexane and heptane; ketones, e.g., acetone and methyl ethyl ketone; chlorinated hydrocarbons, e.g., chloroform, carbon tetrachloride, methylene chloride and ethylene dichloride acetates, e.g., ethyl acetate.
Examples of suitable lubricants include stearic acid, magnesium stearate, sodium stearyl fumarate, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, zinc stearate, calcium stearate, silica, talc, polyethylene glycol, paraffin or the mixtures thereof. The lubricant according to current invention are present in an amount 0.1- 10% w/w.
Suitable anti-tacking agents may be selected from stearates; stearic acid; vegetable oil; waxes; a blend of magnesium stearate and sodium lauryl sulfate; sodium benzoate; sodium acetate and the like.
The surfactants and emulsifiers may be ionic or nonionic. Specific examples of surfactants and emulsifiers are such as poloxamers, polyethylene glycols, polyethylene glycol monostearate, polysorbates, sodium lauryl sulfate, polyethoxylated and hydrogenated castor oil, etc. Moreover, the composition of the present invention may include stabilizers like gums, agar; taste masking agents like acrylic polymers, copolymers of acrylates, celluloses, resins; coloring agents like titanium dioxide, natural food colors, dyes suitable for food, drug and cosmetic applications.
In some embodiments, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin is the bilayer tablet, wherein granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using wet granulation method and granules of Vildagliptin comprising layer is prepared using dry granulation method.
In some embodiments, granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using following steps: i. Mix Remogliflozin etabonate, Metformin, diluent & disntigrant ii. Separately prepared binder solution. iii. Granulate mixture of step (i) using binder solution of step (ii). iv. Dry the wet granules of step (iii).
v. Mix the extra-granular excipients i.e. disintegrant and lubricant with dry granules of step
(iv).
In some embodiments, granules of Remogliflozin etabonate and Metformin hydrochloride comprising layer is prepared using following steps: i. Mix Remogliflozin etabonate, Metformin and L- hydroxypropyl cellulose. ii. Separately prepared binder solution by mixing hydroxyl propyl cellulose with water. iii. Granulate mixture of step (i) using binder solution of step (ii). iv. Dry the wet granules of step (iii). v. Mix L- hydroxypropyl cellulose extra granularly with dry granules of step (iv) and finally add magnesium stearate.
In some embodiments, granules of Vildagliptin comprising layer is prepared using roller compaction process.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein composition is packed in Alu- Alu blister pack.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein the composition is stable at 30°C ± 2°C & 75% RH ± 5 % RH.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and vildagliptin, wherein the composition is stable at 40°C ± 2°C & 75% RH ± 5 % RH.
In another embodiment, the solid oral pharmaceutical composition comprising Remogliflozin etabonate, Metformin hydrochloride and Vildagliptin, wherein composition exhibits a synergistic effect.
The pharmaceutical compositions disclosed herein can be administered to mammalian subjects, preferably humans, for the treatment of type 2 diabetes, impaired glucose tolerance, insulin resistance, and diabetic complications such as hyperglycemia, hyperinsulinemia, and obesity.
EXAMPLES
EXAMPLE 1: Fixed dose combination of Remogliflozin etabonate, Vildagliptin and Metformin hydrochloride.
Manufacturing Process for Example 1 & 2:
I) Manufacturing process for Remogliflozin etabonate & Metformin hydrochloride blend:
1. Milling of Metformin Hydrochloride: 1.1 Mill the Metformin HC1 through multimil using 0.5 mm screen.
1.2 Mix Remogliflozin Etabonate (A), L- Hydroxy propyl cellulose & Metformin HC1 approximately one fourth quantity from step no 1.1 & Sift through # 30 mesh SS sieve
1.3 Co-Sift step 1.2 & remaining quantity of Metformin Hydrochloride through # 30 mesh SS sieve 2. Preparation of binder Solution:
2.1 Dissolve under stirring Hydroxy propyl cellulose (Klucel LF) in water and continue the stirring for 45 minute till the clear is solution obtained
3. Top spray granulation in FBP:
3.1 Load the blend from step 1.3 in to FBP bowl. 3.2 Commence spray of binder solution once bed temperature 33°C ± 5°C is achieved & perform the granulation process
4. Drying:
4.1 Dry the granules of step no. 3.2
4.2 Dry the granules till LOD is within target of 0.9 to 1.3% w/w 5.0 Diminution:
5.1 Sift dried granules through 18 # sieve using vibratory sifter
5.2 Mill the oversized granules through Cad mill /Multimill using 3.0/1.5/1.0 mm sieve/screen and sift through # 18 mesh screen using vibratory sifter.
6.0 Blending & Lubrication:
6.1 Sift using vibratory sifter, L-hydroxy propyl cellullose-through # 40 sieve
6.2 Remove granules of step 6.1 and Mix manually in polybag with sifted L-hydroxy propyl cellullose from step no 6.1 and sift through # 16
6.3 Load the Granules from step 6.1 and Premix blend from step 6.2 into Blender and Mix for 12 minutes at 12 rpm.
6.4 Sift Magnesium stearate through # 60 sieve and collect it in a double polyethylene bag.
6.5 Remove blend from blender (Step 6.3) and Mix manually in double polybag with sifted magnesium stearate (Step 6.4) & Sift through # 16 sieve and add to blender (of step 6.4) and Mix for 3 minutes at 12 rpm.
II) Manufacturing of Vildagliptin Blend
1.0 Sifting:
1.1 Remove approximately half quantity of anhydrous Lactose by sifting suitable quantity through #100 sieve
1.2 Co-Sift through 40 # sieve, Vildagliptin Remaining quantity of anhydrous Lactose and Sodium starch Glycol ate
1.3 Mix Ferric oxide yellow and fines of anhydrous Lactose from step 1.1 and Sift through 100 # sieve
1.4 Co-sift step no 1.2 and 1.3 through #40 sieve
1.5 Sift Magnesium stearate (0.385 kg) through #60 sieve
2.0 Blending and Lubrication for roll compaction:
2.1 Load above sifted ingredient from step 1.4 in to a blender and Mix for 15 minutes at 12 rpm
3.0 Roll Compaction & Sizing:
3.1 Fill the hopper of the Roll Compactor with blend of step 2.2 Compact the blend with the following
Settings and continue with manual feeding of blend.
3.2 After completion of compaction cycle, Pass the flakes/ compacts/ granules/ through ASTM # 30 sieve and take the un-compacted blend for compaction and compacts for sizing.
3.3 Pass the flakes through cad mill / multimill using 6.0 mm sieve/screen & then sift the obtained granules through #30 sieve using vibratory sifter, Collect the oversized & undersized granules separately. Record the speed of Cad mill / multimill.
3.4 Pass the oversized granules if any of step 3.3 through cad mill / multimill using 3.0 mm/1.5/1.0/0.5 sieve/screen & sift the obtained granules through #30 sieve using vibratory sifter.
3.5 In case retention over # 30 sieve is observed, mill the retention through cad mill / multi mill using 0.5 mm sieve/screen and sift through # 30 sieve. Record the speed of cad mill / multimill. Repeat the milling process through 0.5 mm screen till no retention on #30 sieve.
3.6 Check the fine and granules percentages using #60 mesh i.e. above and below 60 mesh.
If Granules quantity is more than 70% of practical weight then proceed for Lubrication, if granules quantity is less than 70% proceed for next roll compaction cycle & sizing using fines.
3.7 Repeat the above roll compaction cycle & sizing till required percent granules are achieved.
4.0 Blending & Lubrication:
4.1 Load granules and fines from step 3.0 in to the blender and mix for 5 minutes at 12 rpm,
4.2 Sift Magnesium stearate through #60 sieve and collect in a double polyethylene bag
4.3 Remove blend from step 4.1 and Mix with sifted magnesium stearate from step 4.2 and Sift through #30 sieve and Load to blender (step 4.1) and Mix for 3 minute.
III) Compression of Bilayer Tablets:
1. Set the Bilayer compression machine using punches.
2. Transfer the both the drugs granules in the separate hopper and adjust machine to set the average weight for Remogliflozin Etabonate and Metformin Hydrochloride layer and Vildagliptin layer as desired
IV) Film Coating of Bilayer Tablets:
1.1 Place Methylene chloride and Isopropyl alcohol in suitable SS vessel equipped with mechanical stirrer and stir the mixture for approximately 2 to 5 minutes.
1.2 Remove Methylene chloride and Isopropyl alcohol mixture from step 1.1, to it add Ferric oxide yellow under stirring and mix approximately for 2 to 5 minutes.
1.3 Pass the color dispersion from step 1.2 through colloid mill for approximately 5 to 15 minutes. Rinse the colloid mill using Methylene chloride and Isopropyl alcohol mixture from step 1.1 and filter it through #200 mesh Nylon cloth.
1.4 Add under stirring Opadry White YS-1- 18202 A into remaining quantity of Methylene chloride and Isopropyl alcohol mixture from step 1.1 and mix it for approximately 5 minutes.
1.5 Add under stirring filtered color dispersion from step 1.3 into Opadry White YS-1- 18202 A dispersion at step 1.4 and continue the stirring for 45 minutes. 1.6 Filter the above coating dispersion from step 1.5 through 200# Nylon cloth and collect in a SS vessel.
2.0 Film coating process:
2.1 Load the tablets in the coating pan
2.2 Carry out the pre warming of tablets for 2 to 5 minutes 2.3 Once the product bed temperature attains 30°C to 35°C, start spraying of coating solution
2.4 Continue the spraying of coating dispersion till the film coverage & target weight gain of 2.0% (Limit 1.5 to 2.5 %) per tablet of pre warmed tablets is achieved by taking average weight of 100 tablets.
2.5 Commence the drying of the tablets in same machine
Example 3: Dissolution data of composition of examples 1 & 2 I) Dissolution data for Remogliflozin etabonate and Vildagliptin:
Stability Analysis:
Stability test was performed for the combined tablet obtained in the above Example 1 & 2 under the following conditions
Example 4: Stability data of composition of Example 1 Condition: 30°C ± 2°C & 75% RH ± 5 % RH
Example 5: Stability data of composition of example 2 Storage condition: 30°C ± 2°C & 75% RH ± 5 % RH
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as described above.
All publications and patent applications cited in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.
Claims
1. A pharmaceutical composition comprising: a) Remogliflozin etabonate in an amount of lOOmg to 250mg b) Metformin hydrochloride in amount of 500mg to lOOOmg, c) Vildagliptin in amount of 50mg to lOOmg, and d) a pharmaceutical acceptable excipient
2. A pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable excipient comprises a diluent, a binder, a lubricant, a disintegrant and a glidant.
3. A pharmaceutical composition according to claim 2, wherein
- diluent is selected from the group comprising anhydrous lactose, microcrystalline cellulose, silicified microcrystalline cellulose, microfme cellulose, lactose, starch, pregelatinized starch, low substituted hydroxy propyl cellulose and mannitol
- binder is selected from group comprising low substituted hydroxy propyl cellulose, hydroxy propyl cellulose, starche, pregelatinize starche, gelatin, polyvinylpyrrolidone, povidone, methylcellulose, sodium carboxymethylcellulose and ethylcellulose
- lubricant is selected from the group comprising stearic acid, magnesium stearate, sodium stearyl fumarate, silica and talc
- disintegrant is selected from the group comprising crosscarmellose sodium, starch, potato starch, corn starch, crospovidone, sodium starch glycolate, microcrystalline cellulose and low substituted hydroxypropyl cellulose
- glidant is selected from group comprising stearic acid, magnesium stearate, talc, colloidal silicon dioxide, and sodium stearyl fumarate.
4. A pharmaceutical composition according to claim 1, wherein the composition provides a dissolution of at least 75% within 45 minute of Remogliflozin etabonate and Vildagliptin in a dissolution media comprising phosphate buffer pH 3.0 and 0.5 % w/w cetyltrimethylammonium bromide and at least 75 % within 45 minute of Metformin hydrochloride in a dissolution media comprising phosphate buffer pH 6.8.
5. A bilayer tablet comprising: a) Remogliflozin etabonate b) Metformin hydrochloride
c) Vildagliptin, and d) a pharmaceutical acceptable excipient wherein first layer of the tablet comprises Remogliflozin etabonate and Metformin hydrochloride and the second layer comprises vildagliptin.
6. A bilayer tablet according to claim 5, wherein the first layer of the tablet comprising Remogliflozin etabonate and Metformin is prepared by wet granulation process and the second layer comprising Vildagliptin is prepared by roller compaction process.
7. A bilayer tablet according to claim 5, wherein the composition provides a dissolution of at least 75 % within 45 minute of Remogliflozin etabonate and Vildagliptin in a dissolution media comprising phosphate buffer pH 3.0 and 0.5 % w/w cetyl trimethyl ammonium bromide and at least 75 % within 45 minute of Metformin hydrochloride in a dissolution media comprising phosphate buffer pH 6.8.
8. A bilayer tablet according to claim 5, wherein the total amount of impurity is not more than 2 % when stored at 30 °C ± 2°C & 75% RH ± 5 % RH & 40°C ± 2°C & 75% RH ± 5 % RH.
9. A bilayer tablet comprising: a first layer of Remogliflozin etabonate and Metformin hydrochloride, a second layer of Vildagliptin and one or more pharmaceutically acceptable excipient comprising
- a diluent in an amount of 5-50% w/w,
- a binder in an amount of 0.1-20% w/w,
- a disintegrant in an amount of 1-30% w/w,
- a lubricant in an amount of 0.1-10% w/w,
- a glidant in an amount of 0.05-5% w/w, wherein the amount of excipient is based on % w/w of the tablet weight.
10. The bilayer tablet according to claim 9, wherein
- the diluent is selected from group comprising anhydrous lactose, microcrystalline cellulose, silicified microcrystalline cellulose, microfme cellulose, lactose, starch, pregelatinized starch, mannitol, low substituted hydroxy propyl cellulose
- the binder is selected from group comprising low substituted hydroxy propyl cellulose, hydroxy propyl cellulose, starches, pregelatinize starches, gelatin,
polyvinylpyrrolidone, povidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose
- the lubricant is selected from group comprising stearic acid, magnesium stearate, sodium stearyl fumarate, silica, talc
- the disintegrant is selected from group comprising crosscarmellose sodium, starch, potato starch, corn starch, crospovidone, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose
- the glidant is selected from group comprising stearic acid, magnesium stearate, talc, colloidal silicon dioxide, and sodium stearyl fumarate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121026505 | 2021-06-14 | ||
IN202121026505 | 2021-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022263935A1 true WO2022263935A1 (en) | 2022-12-22 |
Family
ID=84526212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/051919 WO2022263935A1 (en) | 2021-06-14 | 2022-03-04 | Pharmacutical composition comprising remogliflozin etabonate, metformin hydrochloride and vildagliptin |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022263935A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019162800A1 (en) * | 2018-02-21 | 2019-08-29 | Glenmark Pharmaceuticals Limited | Pharmacutical composition comprising remogliflozin and antidiabetic agent |
WO2020089760A1 (en) * | 2018-11-01 | 2020-05-07 | Glenmark Pharmaceuticals Limited | Fixed dose pharmaceutical composition comprising combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof |
-
2022
- 2022-03-04 WO PCT/IB2022/051919 patent/WO2022263935A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019162800A1 (en) * | 2018-02-21 | 2019-08-29 | Glenmark Pharmaceuticals Limited | Pharmacutical composition comprising remogliflozin and antidiabetic agent |
WO2020089760A1 (en) * | 2018-11-01 | 2020-05-07 | Glenmark Pharmaceuticals Limited | Fixed dose pharmaceutical composition comprising combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2341910B1 (en) | Immediate release dosage forms of sodium oxybate | |
JP6976946B2 (en) | A pharmaceutical composition containing an inhibitor of URAT1 having strong bioactivity. | |
JP2021525739A (en) | Combinations, compositions, combinations of pharmaceuticals containing glucokinase activators and K-ATP channel blockers, and methods and uses thereof. | |
KR20140007247A (en) | Controlled release compositions with reduced food effect | |
ES2609791T3 (en) | Formula for diabetes co-therapy treatments | |
US20060141023A1 (en) | Pharmaceutical compositions containing abiguanide-glitazone combination | |
TWI606848B (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
US20130059002A1 (en) | Pharmaceutical compositions comprising a combination of metformin and sitagliptin | |
EP4051246A1 (en) | Bilayer tablet formulations comprising dapagliflozin and metformin | |
EP4114365A1 (en) | Pharmaceutical composition comprising sglt2 inhibitor | |
WO2020089761A1 (en) | Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof | |
WO2019162800A1 (en) | Pharmacutical composition comprising remogliflozin and antidiabetic agent | |
WO2022263935A1 (en) | Pharmacutical composition comprising remogliflozin etabonate, metformin hydrochloride and vildagliptin | |
EP2468267B1 (en) | Bilayer Combination Composition of Vildagliptin and Gliclazide | |
US20240100011A1 (en) | Pediatric formulations of ferric citrate | |
WO2022036506A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
WO2005102290A1 (en) | Pharmaceutical compositions of a biguanide and a sulfonylurea | |
KR20160141044A (en) | Extended Release Formulation for Oral Administration of Sildenafil | |
WO2023012817A1 (en) | A pharmaceutical composition comprising combination of dapagliflozin and sitagliptin | |
WO2023007511A1 (en) | A pharmaceutical composition comprising combination of sglt2 inhibitor and dpp-iv inhibitor | |
KR20240092879A (en) | Pharmaceutical sustained-release formulation comprising limaprost and method for preparing the same | |
KR20150055986A (en) | Extended Release Formulation for Oral Administration of Bosentan | |
KR100715114B1 (en) | A Medical Formulation for Diabetes | |
WO2019030610A1 (en) | Directly compressible dual drug releasing pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22824373 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22824373 Country of ref document: EP Kind code of ref document: A1 |